Alessandra Siegmann

Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95

Thomas Wiegel, Dirk Bottke, Ursula Steiner et al. · Journal of Clinical Oncology · 2009 · 815 citations

Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96–02/AUO AP 09/95 Trial

Thomas Wiegel, Detlef Bartkowiak, Dirk Bottke et al. · European Urology · 2014 · 444 citations

Urology, Surgical Oncology, Radiation Medicine +9

Achieving an Undetectable PSA After Radiotherapy for Biochemical Progression After Radical Prostatectomy Is an Independent Predictor of Biochemical Outcome—Results of a Retrospective Study

Thomas Wiegel, Gunnar Lohm, Dirk Bottke et al. · International Journal of Radiation Oncology*Biology*Physics · 2008 · 138 citations

Urology, Radiation Medicine, Surgical Oncology +9

Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96–02/AUO AP 09/95)

Thomas Wiegel, Dirk Bottke, Normann Willich et al. · Journal of Clinical Oncology · 2007 · 105 citations

Radiation Medicine, Surgical Oncology, Urology +14

Prostate-Specific Antigen Persistence After Radical Prostatectomy as a Predictive Factor of Clinical Relapse-Free Survival and Overall Survival: 10-Year Data of the ARO 96-02 Trial

Thomas Wiegel, Detlef Bartkowiak, Dirk Bottke et al. · International Journal of Radiation Oncology*Biology*Physics · 2014 · 82 citations

Surgical Oncology, Urology, Genitourinary Cancer +7